Cognitive Impairment in Long-COVID and Its Association with Persistent Dysregulation in Inflammatory Markers
Overview
Authors
Affiliations
Objective: To analyze the potential impact of sociodemographic, clinical and biological factors on the long-term cognitive outcome of patients who survived moderate and severe forms of COVID-19.
Methods: We assessed 710 adult participants (Mean age = 55 ± 14; 48.3% were female) 6 to 11 months after hospital discharge with a complete cognitive battery, as well as a psychiatric, clinical and laboratory evaluation. A large set of inferential statistical methods was used to predict potential variables associated with any long-term cognitive impairment, with a focus on a panel of 28 cytokines and other blood inflammatory and disease severity markers.
Results: Concerning the subjective assessment of cognitive performance, 36.1% reported a slightly poorer overall cognitive performance, and 14.6% reported being severely impacted, compared to their pre-COVID-19 status. Multivariate analysis found sex, age, ethnicity, education, comorbidity, frailty and physical activity associated with general cognition. A bivariate analysis found that G-CSF, IFN-alfa2, IL13, IL15, IL1.RA, EL1.alfa, IL45, IL5, IL6, IL7, TNF-Beta, VEGF, Follow-up C-Reactive Protein, and Follow-up D-Dimer were significantly (p<.05) associated with general cognition. However, a LASSO regression that included all follow-up variables, inflammatory markers and cytokines did not support these findings.
Conclusion: Though we identified several sociodemographic characteristics that might protect against cognitive impairment following SARS-CoV-2 infection, our data do not support a prominent role for clinical status (both during acute and long-stage of COVID-19) or inflammatory background (also during acute and long-stage of COVID-19) to explain the cognitive deficits that can follow COVID-19 infection.
[Cognition and Long COVID: A PRISMA Systematic Review of Longitudinal Studies].
Tudorache Pantazi M, Gadea-Domenech M, Espert Tortajada R Rev Neurol. 2025; 79(12):37385.
PMID: 39910970 PMC: 11799851. DOI: 10.31083/RN37385.
Bidhendi-Yarandi R, Biglarian A, Karlstad J, Moe C, Bakhshi E, Khodaei-Ardakani M PLoS One. 2025; 20(1):e0312351.
PMID: 39874315 PMC: 11774403. DOI: 10.1371/journal.pone.0312351.
Kyriakopoulos A, Nigh G, McCullough P, Seneff S F1000Res. 2024; 13:191.
PMID: 39526116 PMC: 11549548. DOI: 10.12688/f1000research.143517.3.
Cluster analysis identifies long COVID subtypes in Belgian patients.
Mfouth Kemajou P, Besse-Hammer T, Lebouc C, Coppieters Y Biol Methods Protoc. 2024; 9(1):bpae076.
PMID: 39478809 PMC: 11522879. DOI: 10.1093/biomethods/bpae076.
Kulczynska-Przybik A, Czupryna P, Adamczuk J, Kruszewska E, Mroczko B, Moniuszko-Malinowska A Sci Rep. 2024; 14(1):25798.
PMID: 39468309 PMC: 11519350. DOI: 10.1038/s41598-024-76630-4.